Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0929 • ACR Convergence 2022
Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Cara Kumar¹, Kristine Herrmann¹ and Martin Aringer², ¹Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany
Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…
Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Hafsah Nabi¹, Oliver Hendricks², Dorte Vendelbo Jensen³, Anne Gitte Loft⁴, Jens Pedersen⁵, Søren Just⁶, Kamilla Danebod⁷, Heidi Munk⁸, Salome Kristensen⁹, Natalia Manilo¹⁰, Ada Colic¹¹, Asta Linauskas¹², Pia Høger Thygesen¹³, Louise Christensen³, Maren Høgberget Kalisz³, Niels Lomborg¹⁴, Stavros Chrysidis¹⁵, Johnny Raun¹⁵, Marlene Andersen¹⁶, Frank Mehnert¹⁷, Niels Steen Krogh¹⁸, Merete L Hetland¹⁹ and Bente Glintborg²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ³Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Svendborg Hospital, Odense University Hospital, Odense, Denmark, ⁶Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, ⁹Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹¹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹²North Denmark Regional Hospital, Hjørring, Denmark, ¹³Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁴Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Denmark, Odense, Denmark, ¹⁵Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, ¹⁶Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸ZiteLab ApS, Frederiksberg, Denmark, ¹⁹Rigshospitalet, Glostrup, Denmark, ²⁰Rigshospitalet, Glostrup, Virum, Denmark
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…
Abstract Number: 1229 • ACR Convergence 2022
Erosion Score and Erosive Joint Number Using Radiography: Clinical Implications in Patients with ACPA+ Early RA Treated with Abatacept
Chahin Pachai¹, Sean E Connolly², Yoshiya Tanaka³, Vivian Bykerk⁴, Tom Huizinga⁵, Gustavo Citera⁶, Clifton O. Bingham III⁷, Shuyan Du¹, Godehard Hoexter⁸, Paul Emery⁹, Subhashis Banerjee¹ and Roy Fleischmann¹⁰, ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Morrisville, PA, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴Hospital for Special Surgery, New York, NY, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ⁷Johns Hopkins University, Baltimore, MD, ⁸Bristol Myers Squibb GmbH & Co. KGaA, Munich, Germany, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹⁰University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Inhibition of structural joint damage progression is a key outcome measure in RA clinical trials. This can be assessed by progression of joint erosion…
Abstract Number: 1342 • ACR Convergence 2022
Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients
Reid Weisberg¹, Brett Capel¹, Annabelle Guo¹, Komal Patel¹, Rashmi Arora², Swathi Reddy³ and Una Makris⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Dallas VA Medical Center / University of Texas Southwestern Medical Center, Dallas, TX, ³Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: In September 2021, the FDA updated its boxed warnings for Janus Kinase (JAK) inhibitors to include increased risk of major adverse cardiac events (MACE)…
Abstract Number: 1397 • ACR Convergence 2022
The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis
Ozlem Pala¹, Dimitrios Pappas², George Reed³ and Joel Kremer⁴, ¹University of Miami, Fort Lauderdale, FL, ²Corrona Research Foundation; CorEvitas, LLC, Albany, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic, inflammatory disease, and its burden extends beyond joint disease. RA is not commonly associated with central nervous system…
Abstract Number: 1413 • ACR Convergence 2022
Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study
Jie Pan¹, Yao-Wei Zou¹, Ying-Ying Zhu², Jian-da Ma³, Jian-Zi Lin³, Tao Wu¹, Ze-Hong Yang², Xue-Pei Zhang¹, Qian Zhang¹, Hu-Wei Zheng¹, Xiao-Ling He⁴, Wan-Mei Cheng⁴ and Lie Dai³, ¹Sun Yat-Sen University, Guangzhou, China, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴Shanghai Healthare Co. Ltd, Shang hai, China
Background/Purpose: Muscle loss is common in long-standing rheumatoid arthritis (RA) patients. However, less is known about this unfavorable alteration of body composition (BC) and its…
Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Marco Matucci-Cerinic⁴, Eugenio Chamizo Carmona⁵ and Janet Addison⁶, ¹JLU Campus KK, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Cambridge University, Cambridge, United Kingdom, ⁴University of Florence, Florence, Italy, ⁵Hospital de Mérida, Mérida, Spain, ⁶Biogen Idec Ltd, Maidenhead, United Kingdom
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…
Abstract Number: 1607 • ACR Convergence 2022
Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis
Vincent Bouget¹, Julien Duquesne¹, Paul-Henry Cournède², Bruno Fautrel³, Francis Guillemin⁴, Pascal de Jong⁵, Judith Heutz⁶, Marloes Verstappen⁷, Annette van der Helm-van Mil⁸, Xavier Mariette⁹ and Samuel Bitoun¹⁰, ¹Scienta Lab, Paris, France, ²Paris-Saclay University - CentraleSupelec, Paris, France, ³Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁴Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Erasmus Medical Center, Rotterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁰Paris-Saclay University, Paris, France
Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
Abstract Number: 1729 • ACR Convergence 2022
SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis
Mégane Lacaud¹, Houda-Ghozlane Bouzidi¹, Magali Breckler², Delphine Lemeiter², Johanna Sigaux³, Luca Semerano⁴, Marie-Christophe Boissier⁵, Natacha Bessis⁶ and Jerome Biton⁷, ¹Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, ²Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ³Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, ⁴Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, ⁵INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, ⁶INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, ⁷INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France
Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
Abstract Number: 1765 • ACR Convergence 2022
Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
Ana Pons¹, José Rosas¹, José Miguel Senabre², JC Cortés-Quiroz¹, Carmen Raya-Santos², Gregorio Santos-Soler², Lara Pons², Marisa Lorente², José Antonio Bernal³, Xavier Barber⁴ and José Alberto Garciía-Gómez⁴, ¹Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain, ²Hospital Marina Baixa, Villajoyosa, Spain, ³Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁴CIO Miguel Hernández University Elche, Alicante, Spain
Background/Purpose: Patients receiving treatment with JAK inhibitor drugs (JAKi) have an increased risk of developing herpes zoster (HZ). A new recombinant vaccine effective against HZ…
Abstract Number: 1956 • ACR Convergence 2022
Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study
Sarah J.H. Khidir¹, Bastiaan van Dijk², Marloes Verstappen¹, Elise van Mulligen³ and Annette van der Helm-van Mil⁴, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Erasmus Medical Center, Leiden University Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: In the pre-arthritis phase of Rheumatoid Arthritis (RA), symptoms resulting in physical disabilities already occur. It is unknown whether functional disabilities start in hands…
Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Daniela Grimaldi¹, Kathryn Reid¹, Phyllis Zee¹, Rowland Chang⁴ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Evanston, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…
Abstract Number: 1991 • ACR Convergence 2022
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
Siba Raychaudhuri¹, Smriti Raychaudhuri² and Heike Wulff³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²VA Medical Center, Sacramento, CA, ³UC Davis, Davis, CA
Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1.…
Abstract Number: 2007 • ACR Convergence 2022
Rheumatoid Arthritis Associated Lymphoproliferative Disorders: Current Features and It’s Changing Pattern Due to the Influence of Anti-rheumatic Drugs
Yoshihiko Hoshida¹, Atsuko Tsujii², Shiro Ohshima², Yukihiko Saeki², Masato Yagita³, Tomoya Miyamura⁴, Masao Katayama⁵, Yasushi Hiramatsu⁶, Hisaji Oshima⁷, Toshihiko Murayama⁸, Shinji Higa⁹, Fuminori Hirano¹⁰, Kenji Ichikawa¹¹, Noriyuki Chiba¹², Takao Sugiyama¹³, Atsushi Ihata¹⁴, Akiko Mitsuo¹⁵, Hiroshi Tsutani¹⁶, Koichiro Takahi¹⁷, Akira Okamoto¹⁸, Shigeru Yoshizawa¹⁹, Yasuo Suenaga²⁰, Shunsuke Mori²¹, Shoichi Nagakura²², Norie Yoshikawa²³, Atsuhisa Ueda²⁴, Shouhei Nagaoka²⁵, Keigo Setoguchi²⁶, Shoji Sugii²⁷, Asami Abe²⁸, Toshiaki Sugaya²⁹, Masahiro Koseto³⁰, Yasuo Kunugiza³¹, Norishige Iizuka³², Ryosuke Yoshihara³³, Tomoaki Fujisaki³⁴, Hiroyuki Sugahara³⁵, Ikuo Saito³⁶, Kazuya Kuraoka³⁷, Norihiro Teramoto³⁸, Masahiro Ito³⁹, Kenichi Taguchi⁴⁰, Yuko Minami⁴¹, Shinji Naito⁴², Mitsuharu Nomoto⁴³, Kazuyoshi Saito⁴⁴, Kiyoshi Matsui⁴⁵, Yasuhiko Tomita⁴⁶, Hiroshi Furukawa⁴⁷ and Shigeto Tohma⁴⁸, ¹Department of Pathology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ²Department of Rheumatology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ³Division of Inflammation and Immunity, Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Osaka, Japan, ⁴Department of Rheumatology, NHO Kyushu Medical Center, Fukuoka, Japan, ⁵Department of Rheumatology, NHO Nagoya Medical Center, Nagoya, Japan, ⁶Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁷National Hospital Organization Tokyo Medical Center, Meguroku, Japan, ⁸Department of Pathology, NHO Kumamoto Medical Center, Kumamoto, Kumamoto, Japan, ⁹Division of Rheumatology, Daini Osaka Police Hospital, Osaka, Osaka, Japan, ¹⁰Department of Rheumatology, NHO Asahikawa Medical Center, Asahikawa, Hokkaido, Japan, ¹¹Department of Rheumatology, NHO Hokkaido Medical Center, Sapporo, Japan, ¹²epartment of Rheumatology, NHO Morioka Medical Center, Morioka, Japan, ¹³Department of Rheumatology, NHO Shimoshizu Hospital, SIkaido, Chiba, Japan, ¹⁴Department of Rheumatology, NHO Yokohama Medical Center, Yokohama, Japan, ¹⁵Department of Rheumatology, NHO Disaster Medical Center, Tachikawa, Japan, ¹⁶Department of Rheumatology, NHO Awara Hospital, Awara, Fukui, Japan, ¹⁷Department of Rheumatology, NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ¹⁸Department of Rheumatology, NHO Himeji Medical Center, Himeji, Japan, ¹⁹Department of Rheumatology, NHO Fukuoka Hospital, Fukuoka, Japan, ²⁰Department of Rheumatology, NHO Beppu Medical Center, Beppu, Oita, Japan, ²¹Department of Rheumatology, NHO Kumamoto Saishun Medical Center, Goshi, Japan, ²²Department of Hematology, NHO Kumamoto Minami Hospital, Ushiro, Japan, ²³Department of Rheumatology, NHO Miyakonojo Medical Center, Miyakonojo, Japan, ²⁴Department of Rheumatology, Yokohama City University, Yokohama, Japan, ²⁵Department of Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²⁶Department of Systemic immunological diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, ²⁷Department of Internal Medicine, Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ²⁸Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²⁹Department of Rheumatology, Fuchu Hospital, Izumi, Japan, ³⁰Department of Laboratory Medicine and Internal Medicine (Clinical Immunology), Nippon Life Hospital, Osaka, Osaka, Japan, ³¹Department of Orthopedics, JCHO Hoshigaoka Medical Center, Hirakata, Japan, ³²Department of Pathology, Kishiwada City Hospital, Kishiwada, Japan, ³³Department of Rheumatology, Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ³⁴Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan, ³⁵Department of Hematology, Sumitomo Hospital, Osaka, Osaka, Japan, ³⁶Department of Pathology, NHO Sagamihara Hospital, Sagamihara, Kanagawa, Japan, ³⁷Department of Diagnostic Pathology, NHO Kure Medical Center /Chugoku Cancer Center, Kure, Hiroshima, Japan, ³⁸Department of Pathology, NHO Shikoku Cancer Center, Matsuyama, Japan, ³⁹Department of Pathology, NHO Nagasaki Medical Center, Nagasaki, Japan, ⁴⁰Department of Pathology, NHO Kyushu Cancer Center, Fukuoka, Japan, ⁴¹Department of Pathology, NHO Ibarakihigashi Hospital, Nakagun, Japan, ⁴²Department of Pathology, NHO Ureshino Medical Center, Ureshino, Japan, ⁴³Department of Pathology, NHO, Kagoshima Medical Center, Kagoshima, Japan, ⁴⁴First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴⁵Hyogo College of Medicine, Nishinomiya, Japan, ⁴⁶Department of Pathology, International University of Health and Welfare, Narita, Japan, ⁴⁷Department of Rheumatology, NHO Tokyo National Hospital, Tokyo, Japan, ⁴⁸National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: The effect of antirheumatic drugs on the development of lymphoproliferative disorders (LPDs) in rheumatoid arthritis (RA) patients remains unclear. The current study aimed to…
Abstract Number: 2188 • ACR Convergence 2022
The Effect of Group-based Cognitive Behavioral Therapy for Insomnia in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Kristine Latocha¹, Katrine Loeppenthin², Mikkel Østergaard³, poul jennum⁴, Merete L Hetland⁵, Henrik Rogind⁶, Tine Lundbak⁶, Julie Midtgaard⁷, Robin Christensen⁸ and Bente Esbensen⁵, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Copenhagen University Hospital - Rigshospitalet, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, ⁵Rigshospitalet, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital -Rigshospitalet, Glostrup, Denmark, ⁷Mental Health Centre Glostrup, University of Copenhagen, Glostrup,Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ⁸Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Insomnia is highly prevalent in people with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain (1).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].